Adoptive cellular immunotherapy for the treatment of malignant gliomas Article Conference Paper uri icon


MeSH Major

  • Astrocytoma
  • Brain Neoplasms
  • Glioblastoma
  • Quinazolines


  • IL-2 plus autogeneic LAK cells can be safely administered intracavitary to treat high grade primary brain tumors with limited toxicity within the central nervous system. Six out of 28 patients had long-term survival of greater than 2 years post-reoperation plus immunotherapy with 2 patients alive over 8 years. The presence of a marked regional eosinophilia appeared to correlate with increased survival and may be predictive of a biologic and therapeutic response. Regional adoptive immune therapy was well tolerated and should be considered an option for patients with high-grade tumors refractive to standard therapeutic approaches.

publication date

  • July 3, 2001



  • Conference Paper


Digital Object Identifier (DOI)

  • 10.1016/S1040-8428(01)00122-6

PubMed ID

  • 11418300

Additional Document Info

start page

  • 31

end page

  • 42


  • 39


  • 1-2